Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash from Investing Activities (2016 - 2025)

IGC Pharma (IGC) has disclosed Cash from Investing Activities for 16 consecutive years, with -$374000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 475.38% to -$374000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$40000.0, a 93.1% increase, with the full-year FY2025 number at -$442000.0, down 39.43% from a year prior.
  • Cash from Investing Activities was -$374000.0 for Q3 2025 at IGC Pharma, down from $580000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $1.9 million in Q1 2021 to a low of -$553000.0 in Q1 2022.
  • A 5-year average of $20947.4 and a median of -$65000.0 in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 2520.0% in 2024, then soared 542.75% in 2025.
  • IGC Pharma's Cash from Investing Activities stood at -$49000.0 in 2021, then surged by 65.31% to -$17000.0 in 2022, then tumbled by 258.82% to -$61000.0 in 2023, then plummeted by 70.49% to -$104000.0 in 2024, then plummeted by 259.62% to -$374000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Cash from Investing Activities are -$374000.0 (Q3 2025), $580000.0 (Q2 2025), and -$142000.0 (Q1 2025).